These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32294103)

  • 21. PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.
    Roper E; Lum T; Palme CE; Ashford B; Ch'ng S; Ranson M; Boyer M; Clark J; Gupta R
    Pathology; 2017 Aug; 49(5):499-505. PubMed ID: 28666643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
    Ren M; Dai B; Kong YY; Lv JJ; Cai X
    Histopathology; 2018 Sep; 73(3):386-396. PubMed ID: 29637587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT).
    Machado I; López-Guerrero JA; Scotlandi K; Picci P; Llombart-Bosch A
    Virchows Arch; 2018 May; 472(5):815-824. PubMed ID: 29445891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
    Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
    Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
    Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
    J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.
    Mansfield AS; Aubry MC; Moser JC; Harrington SM; Dronca RS; Park SS; Dong H
    Ann Oncol; 2016 Oct; 27(10):1953-8. PubMed ID: 27502709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
    Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T
    Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
    Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
    Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value.
    Kim A; Lee SJ; Kim YK; Park WY; Park DY; Kim JY; Lee CH; Gong G; Huh GY; Choi KU
    Sci Rep; 2017 Sep; 7(1):11671. PubMed ID: 28916815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Heterogeneity in PD-L1 expression on infiltrating immune cells between the primary and metastatic breast cancers].
    Wang XR; Zhang NN; Lyu F; Wang HL; Liu YP
    Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):430-434. PubMed ID: 32392925
    [No Abstract]   [Full Text] [Related]  

  • 31. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
    Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
    Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
    Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA
    Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma.
    Feng Y; Shen J; Gao Y; Liao Y; Cote G; Choy E; Chebib I; Mankin H; Hornicek F; Duan Z
    Oncotarget; 2015 May; 6(13):11139-49. PubMed ID: 25871477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
    Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
    Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
    Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P
    PLoS One; 2017; 12(8):e0183023. PubMed ID: 28797130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8
    van Erp AEM; Versleijen-Jonkers YMH; Hillebrandt-Roeffen MHS; van Houdt L; Gorris MAJ; van Dam LS; Mentzel T; Weidema ME; Savci-Heijink CD; Desar IME; Merks HHM; van Noesel MM; Shipley J; van der Graaf WTA; Flucke UE; Meyer-Wentrup FAG
    Oncotarget; 2017 Sep; 8(41):71371-71384. PubMed ID: 29050367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.
    Téglási V; Pipek O; Lózsa R; Berta K; Szüts D; Harkó T; Vadász P; Rojkó L; Döme B; Bagó AG; Tímár J; Moldvay J; Szállási Z; Reiniger L
    Clin Lung Cancer; 2019 Sep; 20(5):363-369.e2. PubMed ID: 31178388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.
    He Y; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Yu H; Zhou C; Hirsch FR
    Med Sci Monit; 2017 Mar; 23():1208-1216. PubMed ID: 28275222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed cell death ligand-1 (PD-L1) expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N anti-PD-L1 antibodies.
    Ahn S; Lee Y; Kim JW; Lee JC; Hwang JH; Yoon YS; Cho JY; Han HS; Choi Y; Kim H
    Histopathology; 2019 Oct; 75(4):526-536. PubMed ID: 31081949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.